Department of Ophthalmology, Royal College of Surgeons in Ireland, D02 XK51 Dublin, Ireland.
School of Pharmacy and Biomolecular Sciences (PBS), RSCI Research Institute, Royal College of Surgeons in Ireland, D02 XK51 Dublin, Ireland.
Viruses. 2021 Sep 17;13(9):1856. doi: 10.3390/v13091856.
Herpes stromal keratitis (HSK) is a disease that commonly affects the cornea and external eye and is caused by Herpes Simplex Virus type 1 (HSV-1). This virus infects approximately 66% of people worldwide; however, only a small portion of these people will develop symptoms in their lifetime. There is no cure or vaccine available for HSV-1; however, there are treatments available that aim to control the inflammation caused by the virus and prevent its recurrence. While these treatments are beneficial to those suffering with HSK, there is a need for more effective treatments to minimise the need for topical steroids, which can have harmful effects, and to prevent bouts of disease reactivation, which can lead to progressive corneal scarring and visual impairment. This review details the current understanding of HSV-1 infection and discusses potential novel treatment options including microRNAs, TLRs, mAbs, and aptamers.
单纯疱疹性基质角膜炎（HSK）是一种常见的角膜和眼外疾病，由单纯疱疹病毒 1 型（HSV-1）引起。这种病毒感染了全球约 66%的人；然而，这些人中只有一小部分在他们的一生中会出现症状。目前尚无针对 HSV-1 的治愈方法或疫苗；然而，有一些治疗方法可以控制病毒引起的炎症并预防其复发。虽然这些治疗方法对 HSK 患者有益，但需要更有效的治疗方法来减少对局部类固醇的需求，局部类固醇可能有有害影响，并预防疾病的复发，这可能导致进行性角膜瘢痕和视力损害。这篇综述详细介绍了对 HSV-1 感染的现有认识，并讨论了包括 microRNAs、TLRs、mAbs 和适体在内的潜在新的治疗选择。
